Cannabis Science (CBIS) Names Investor Relations Veteran Of Leading Companies To Head Its Investor Relations Initiatives
COLORADO SPRINGS, Colo., March 31, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS) today announced it has entered into a one-year agreement with Derwin A. Wallace to provide financial and investor relations services for the Company. Mr. Wallace will focus on developing and expanding the Company's financial communications with the institutional and retail investment communities and initiate coverage from research analysts through a comprehensive financial and investor relations program.
"I am committed to putting all of my financial and operational resources to work to help expedite company processes, and I am looking forward to speaking with our shareholders about the multiple drug development programs, product releases and patient education systems strategies in motion," said Mr. Wallace.
"I expect my efforts should help speed up project results and grow the operational cash flow in a faster time frame," he added. "A number of key projects are underway, such as the Spain and California product releases, Netherlands pre-lab discussions, London, Italy and Africa drug development projects, Coloradoand Washington State formulation releases, and Michigan State and NY State initiatives. Projected potential revenues reflect these projects. That, coupled with smart strategic moves the Company is making, indicates the future of medical cannabis is here, and all this doesn't even 'scratch the surface' of the real growth potential of this Company."
Mr. Raymond C. Dabney, President & CEO of Cannabis Science, Inc., said the new agreement "reflects our commitment to our shareholders to create shareholder value by setting into motion the $5M – $25M and larger capital raises required to take the Company and our suite of products to the next level. With so much going on in the world of medical cannabis and such rapid change, investors and analysts need to be able to make rapid, educated decisions. Adding Mr. Wallace to the team is our most significant, recent step in accomplishing just that, and Mr. Wallace has the experience and expertise to help us tell our story in a professional and transparent manner."
Prior to contracting with Cannabis Science, Mr. Wallace accumulated more than 15 years of investor relations experience at companies including Home Depot, Cox Cable, First Data, and ResCare. As an investor relations professional, Mr. Wallace has extensive experience communicating with and educating institutional investors, retail investors and research analysts, including those interested in the medical cannabis industry. In 2014, Mr. Wallace decided to bring his investor relations experience to the cannabis sector and assisted in creating the Cannabis Investor Conference and founded the Cannabis Investor Webcast. Mr. Wallace holds an MBA with a concentration in Finance from Keller Graduate School of Management and a Bachelors of Science in Accounting from DeVry University.
"The drug development and contemplated growth programs that are underway strongly suggest a path of events and milestones of immense proportions," said Mr. Wallace. "The multitude of projects the Company has underway is spellbinding to say the least, categorizing and creating a timeline is the only way to stay adequately informed. It is astounding the amount of work this Company has put in over the years to get to this point, and it inspires me to join an organization with that level of commitment."
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.